Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D02ECG
|
|||
| Former ID |
DIB003667
|
|||
| Drug Name |
Sodium pyruvate
|
|||
| Synonyms |
SODIUM PYRUVATE; 113-24-6; Pyruvic acid sodium salt; sodium 2-oxopropanoate; Pyruvic acid, sodium salt; Propanoic acid, 2-oxo-, sodium salt; Sodium alpha-ketopropionate; 2-Oxopropanoic acid sodium salt; UNII-POD38AIF08; POD38AIF08; CHEBI:50144; Natriumpyruvat; alpha-Ketopropionic acid sodium salt; MFCD00002586; Propanoic acid, 2-oxo-, sodium salt (1:1); S-6005; Pyruvic acid, sodium salt, 99+%; Pyruvate Sodium; Natrum pyruvicum; CHEMBL181886; sodiumpyruvate; Guna-flam; Guna-hypertension; EINECS 204-024-4; pyruvic acid na-salt; N-115; Sodium pyruvate (inhaled); Reactive oxygen species antagonist (inhaled), EmphyCorp; Sodium pyruvate (inhaled), EmphyCorp; PYRUVATE SODIUM
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Asthma [ICD-11: CA23; ICD-10: J45, J45.8; ICD-9: 493] | Phase 1/2 | [1] | |
| Company |
EmphyCorp Inc
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C3H3NaO3
|
|||
| Canonical SMILES |
CC(=O)C(=O)[O-].[Na+]
|
|||
| InChI |
1S/C3H4O3.Na/c1-2(4)3(5)6;/h1H3,(H,5,6);/q;+1/p-1
|
|||
| InChIKey |
DAEPDZWVDSPTHF-UHFFFAOYSA-M
|
|||
| CAS Number |
CAS 113-24-6
|
|||
| PubChem Compound ID | ||||
| ChEBI ID |
CHEBI:50144
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Carbonic anhydrase IV (CA-IV) | Target Info | Inhibitor | [2] |
| Reactive oxygen species (ROS) | Target Info | Antagonist | [3] | |
| KEGG Pathway | Nitrogen metabolism | |||
| Proximal tubule bicarbonate reclamation | ||||
| Reactome | Erythrocytes take up carbon dioxide and release oxygen | |||
| Erythrocytes take up oxygen and release carbon dioxide | ||||
| Reversible hydration of carbon dioxide | ||||
| WikiPathways | Reversible Hydration of Carbon Dioxide | |||
| Uptake of Carbon Dioxide and Release of Oxygen by Erythrocytes | ||||
| Uptake of Oxygen and Release of Carbon Dioxide by Erythrocytes | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00262652) Safety and Efficacy Study of the Use of Sodium Pyruvate Bronchodilation in Asthmatics. U.S. National Institutes of Health. | |||
| REF 2 | Carbonic anhydrase inhibitors. Interaction of isozymes I, II, IV, V, and IX with carboxylates. Bioorg Med Chem Lett. 2005 Feb 1;15(3):573-8. | |||
| REF 3 | A molecular mechanism of pyruvate protection against cytotoxicity of reactive oxygen species in osteoblasts. Mol Pharmacol. 2006 Sep;70(3):925-35. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.